Table 2 Pyrosequencing diagnostic performance by clinical site
|  | India (n = 492) | Moldova (n = 226) | South Africa (n = 196) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | Sensitivity | Specificity | Agreement | Sensitivity | Specificity | Agreement | Sensitivity | Specificity | Agreement |
INH | 98 % (0.96–0.99) | 97 % (0.90–1) | 98 % (0.96–0.99) | 94 % (0.88–0.97) | 96 % (0.87–0.99) | 95 % (0.90–0.97) | 71 % (0.53–0.85) | 94 % (0.87–0.98) | 88 % (0.81–0.93) |
RIF | 98 % (0.95–0.99) | 100 % (0.94–1) | 98 % (0.96–0.99) | 94 % (0.86–0.98) | 100 % (0.92–1) | 97 % (0.92–0.99) | 77 % 0.54–0.91) | 98 % (0.91–1) | 94 % (0.87–0.97) |
MOX | 96 % (0.92–0.98) | 96 % (0.92–0.98) | 96 % (0.94–0.98) | 67 % (0.39–0.87) | 100 % (0.97–1) | 97 % (0.92–0.99) | 82 % (0.48–0.97) | 99 % (0.96–1) | 98 % (0.94–1) |
OFX | 96 % (0.93–0.98) | 99 % (0.96–1) | 97 % (0.95–0.99) | 64 % (0.36–0.86) | 99 % (0.96–1) | 96 % (0.91–0.98) | 90 % (0.54–0.99) | 99 % (0.96–1) | 99 % (0.95–1) |
AMK | 94 % (0.82–0.98) | 100 % (0.98–1) | 99 % (0.98–1) | 33 % (0.11–0.65) | 99 % (0.96–1) | 95 % (0.91–0.98) | 92 % (0.60–1) | 98 % (0.94–0.99) | 98 % (0.93–0.99) |
KAN | 89 % (0.76–0.95) | 100 % (0.98–1) | 99 % (0.97–0.99) | 7 % (0.02–0.18) | 99 % (0.95–1) | 71 % (0.64–0.77) | 92 % (0.60–1) | 98 % (0.94–0.99) | 97 % (0.94–0.99) |
KAN (+eis) | 93 % (0.81–0.98) | 91 % (0.88–0.94) | 91 % (0.88–0.94) | 79 % (0.66–0.88) | 95 % (0.90–0.98) | 90 % (0.85–0.94) | 92 % (0.60–1) | 98 % (0.93–0.99) | 97 % (0.93–0.99) |
CAP | 94 % (0.81–0.98) | 99 % (0.98–1) | 99 % (0.97–0.99) | 40 % (0.14–0.73) | 99 % (0.96–1) | 96 % (0.92–0.98) | 85 % (0.54–0.97) | 98 % (0.94–0.99) | 97 % (0.92–0.99) |